The effect of disease modifying therapies on CD62L expression in multiple sclerosis.

Mult Scler J Exp Transl Clin 2018 Jul-Sep;4(3):2055217318800810. Epub 2018 Sep 20.

Department of Neurology, Medical University of Graz, Austria.

Background: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear.

Objective: To investigate the effect of various disease-modifying therapies in multiple sclerosis on CD62L expression of CD3CD4 peripheral blood mononuclear cells in freshly collected blood samples.

Methods: We collected peripheral blood samples from patients with clinically isolated syndrome and multiple sclerosis (baseline/follow up  = 234/ = 98) and healthy controls ( = 51). CD62LCD3CD4 expression was analysed within 1 hour by fluorescence-activated cell sorting.

Results: CD62LCD3CD4 expression was significantly decreased in patients treated with natalizumab ( = 26) and fingolimod ( = 20) and increased with dimethyl-fumarate ( = 15) compared to patients receiving interferon/glatiramer acetate ( = 90/30) or no disease-modifying therapies ( = 53) and controls ( = 51) (<0.001). CD62L expression showed temporal stability during unchanged disease-modifying therapy usage, but increased after natalizumab withdrawal and decreased upon fingolimod introduction.

Conclusion: CD62LCD3CD4 expression is altered in patients treated with different disease-modifying therapies when measured in freshly collected samples. The clinical meaning of CD62L changes under disease-modifying therapies warrants further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1177/2055217318800810DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149021PMC
September 2018
19 Reads

Publication Analysis

Top Keywords

multiple sclerosis
16
peripheral blood
12
disease-modifying therapies
12
cd62l expression
12
mononuclear cells
8
therapies multiple
8
cd62lcd3cd4 expression
8
blood mononuclear
8
controls  = 51
8
expression
5
samplesmethods collected
4
blood samplesmethods
4
collected blood
4
syndrome multiple
4
collected peripheral
4
sclerosis baseline/follow
4
samples patients
4
isolated syndrome
4
freshly collected
4
clinically isolated
4

References

(Supplied by CrossRef)

Hegen H et al.
Drugs 2016

Grewal IS et al.
Immunity 2001

Schwab N et al.
Neurology 2013

Spadaro M et al.
J Neuroinflammation 2015

Böhler T et al.
Nephrol Dial Transplant 2004

Schneider-Hohendorf T et al.
Aids 2014

Pignolet B et al.
Neurology 2016

Basnyat P et al.
Mult Scler Relat Disord 2015

Lieberman L et al.
Neurology 2016

Polman CH et al.
Ann Neurol 2005

Similar Publications